Read Occupational Therapist Samar Muslemani’s Early Career Blog
Read the latest early career blog post, from NMD4C member Samar Muslemani, OT, M.Sc.
Excerpt:
“Occupational therapy is where science, creativity, and compassion collide”
This is a quote from Jessica Kensky, a survivor of the 2013 Boston Marathon bombing and keynote speaker at the 2016 American Occupational Therapy Association welcome ceremony. To me, this quote represents exactly what I love about my profession. Pursuing a PhD allows me to develop these three elements even further.
Samar Muslemani holds a Master’s Degree in Occupational Therapy and has been practicing in Saguenay, Québec since 2018. She is a doctoral student with the University of Sherbrooke. She aims to better understand the functional impacts of cognitive impairments in people living with myotonic dystrophy type 1. She completed a research Master’s Degree in Health Sciences in August 2021. Her project aimed to document independence and social participation of adults living with childhood phenotype of DM1. She received a bursary of the Fonds de recherche du Québec – Santé (FRQS), and has assessed patients both in Canada and France as part of her research project. Native from Saguenay-Lac-Saint-Jean region, she is interested in offering more support to patients and families with neuromuscular diseases (NMD) in her native region and internationally. Both in her research and clinical practice, she has worked with various NMDs, such as recessive spastic ataxia of Charlevoix-Saguenay, oculopharyngeal muscular dystrophy and Charcot-Marie-Tooth diseases. She is the first author of a practical guideline to support occupational therapists in addressing sexuality with their NMD patients.
Within the NMD4C, Samar supports the Knowledge Translation team through developing knowledge and skills, defining barriers, and reducing the knowledge-to-action gap by developing various tools including clinical practice guidelines in the NMD field.
Read next...
New Publication from the NMD4C Clinical Trial Network Strengthens Trial Capacity in Canada
We are pleased to share a new publication from the NMD4C Clinical Trial Network led by Kerri Lynn Schellenberg, Homira Osman, Maria Masnata, Rhiannon Hicks, Corinne Kagan, Ana Stosic, Stacey Lintern, Erin Beattie, Drs. Hanns Lochmüller, Craig Campbell, and Jean K Mah. This work focuses on the implementation of a coordinated Canadian neuromuscular clinical trial network to enhance trial readiness, capacity, and access in rare disease research.
Canadian-Led Phase II Studies Advance Vamorolone Evidence in Duchenne Muscular Dystrophy
NMD4C investigators contributed to two phase II studies evaluating vamorolone in boys with Duchenne muscular dystrophy across early childhood and adolescence, demonstrating safety, favorable pharmacokinetics, and potential efficacy. Led by Dr. Jean Mah and conducted across Canadian clinical trial sites with national and industry collaborators, the findings supported Health Canada approval of vamorolone as the first treatment for DMD in Canada. Leaders from both the clinical and patient advocacy communities, including Defeat Duchenne Canada, highlighted the impact of collaboration among patients, families, clinicians, and researchers in advancing care and improving access to new therapies.
Advancing AFC in Neuromuscular Medicine: Program Launch & September Workshop
The Royal College has approved National Training Standards for the AFC in Neuromuscular Medicine, creating a formal pathway to recognize enhanced competence with the DRCPSC credential. This designation establishes a national training standard, supports portable certification, and strengthens clinical capacity across Canada. PGME offices can now apply to offer accredited AFC programs, with a goal of five programs submitting applications by the end of 2026.